IOVA
Iovance BiotherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-20
Current thesis
The stock is depressed versus a median analyst target near $9.56 while Iovance now has a commercial product, a visible launch-conversion setup, and multiple registrational shots on goal beyond current melanoma use.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +17.8.
What can break
Amtagvi demand may not convert cleanly from center onboarding and Proleukin ordering into sustained infusion volume.
Momentum
72
Value
41
Sentiment
31
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.40 · Bull $6.00 · Bear $2.20
Data freshness
Prices
As of 2026-07-20
Fundamentals
As of 2026-07-20 • Vendor: Data Vendor v1
Scores
As of 2026-07-20 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-20
Investment thesis
As of 2026-07-20
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $8.80
Why
Momentum72 · Δ7d +17.8
Value41 · Δ7d +0.0
Sentiment31 · Δ7d -18.9
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
72
26% active weight
Current posture
7d trendImproving
Δ7d
+17.8
Δ21d
-16.1
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
+0.0
Δ21d
-0.1
Sentiment
31
34% active weight
Current posture
7d trendSoftening
Δ7d
-18.9
Δ21d
-16.5
Why this grade
Composite grade D. Momentum 72.0 / Value 41.1 / Sentiment 31.4
Fundamentals (TTM)As of 2026-07-20
Fundamentals (TTM)
As of 2026-07-20
Market Cap
$2.24B
Beta
0.77
Shares Out
446.5M
P/E (TTM) · Derived
-4.6
P/S (TTM)
3.88
P/FCF (TTM) · Derived
-6.20
Rev YoY
+44.8%
EPS YoY
-47.5%
Gross Margin
+25.0%
Op Margin
-166.3%
Net Debt
-$247.54M
Current Ratio
3.60
As of 2026-07-20 • Updated nightlySource: Internal modelMethodology